The on-demand video of the webinar “CDK4/6 Inhibition in Early and Advanced Breast Cancer – Recent data and controversies 2024“ is now available!
14.11.2024The virtual continuing education event “CDK4/6 Inhibition in Early and Advanced Breast Cancer – Recent Data and Controversies 2024” took place on Wednesday, October 30th, 2024, from 5:30 to 7:30 pm CET. A total of 116 participants from 15 countries joined the webinar, which was moderated by ABCSG President Michael Gnant.
In Part 1, the focus was on CDK4/6 inhibitors in metastatic hormone receptor-positive breast cancer. Gabriel Rinnerthaler (ABCSG, Medical University Graz) began with an overview of standard therapies in the first and second line, followed by Cristina Saura (SOLTI, Vall d’Hebron University Hospital, Barcelona), who discussed the sequencing of CDK4/6 inhibitors and assessing endocrine responsiveness.
Part 2 centered on the latest data for adjuvant use of CDK4/6 inhibitors. Wolfgang Janni (University Clinic Ulm) presented recent findings from the NATALEE trial, and Nadia Harbeck (Breast Center, LMU University Hospital, Munich) shared the newest results from the monarchE trial. Christian Singer (ABCSG Vice President, Medical University Vienna) addressed which CDK4/6 inhibitor may best suit specific early breast cancer (eBC) patients.
The event concluded with a panel discussion on recent controversies and clinical implications, chaired by ABCSG president Michael Gnant. All speakers, joined by additional discussants including Marija Balic (University of Pittsburgh School of Medicine), Rupert Bartsch, and Georg Pfeiler (both ABCSG, University Hospital Vienna), engaged in a dynamic discussion.
We would like to thank our sponsors Novartis and Lilly and all speakers and panelists for their informative presentations and their engaging input in the discussion.
For those who have missed the webinar, the on-demand video of the virtual meeting is now available in the → ABCSG Members Area.
More posts on the topic:
Webinar, CDK4/6 Inhibitors
Share on